News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
BioPharm Executive - Bench To Clinic
Gilead Sciences, Inc. (GILD)'s Experimental Drug Simtuzumab Fails Mid-Stage Study 9/19/2014
Eli Lilly and Company (LLY)'s Diabetes Drug Trumps Sanofi (France) (SAN.PA)'s In Phase 3 Trials 9/5/2014
Exelixis, Inc. (EXEL) Chops 70 Percent Of Workforce After Prostate Drug Cabozantinib Fails Pivotal Study 9/4/2014
Early Phase 3 Data Suggest Sanofi (France) (SAN.PA), Regeneron Pharmaceuticals, Inc. (REGN) Drug May Halve Heart Risk 9/3/2014
Amgen (AMGN)'s Cholesterol Lowering Drug Succeeds In Phase 3 Trial 8/29/2014
Gilead Sciences, Inc. (GILD) Shaky As Achillion Pharmaceuticals, Inc. (ACHN)'s Hepatitis C Drug Cures All Patients In Mid-Stage Trial 8/27/2014
Amicus Therapeutics, Inc. (FOLD) Rockets On Positive Phase 3 Study Data For Rare Disease Drug 8/21/2014
Good News For Amgen (AMGN) As Parathyroid Drug AMG 416 Succeeds In Phase 3 Study 8/20/2014
Intercept Pharmaceuticals (ICPT) Soars As Liver Drug Found Effective In Mid-Stage Trial 8/13/2014
Amgen (AMGN) Drug Kyprolis Helped Patients Live 8.7 Months Longer In Late-Stage Trial 8/5/2014
Puma Biotechnology (PBYI) Shares Soar On Breast Cancer Drug Results 7/28/2014
Exelixis, Inc. (EXEL) And Genentech (RHHBY)'s Melanoma Combination Drug Meets Main Goal In Phase 3 Study 7/15/2014
Novartis AG (NVS) To Test Alzheimer's Drugs In Patients Without Symptoms 7/15/2014
Latest Sarepta Therapeutics (SRPT) Phase 2 Data Shows Greater Decline in Walking Ability For Muscular Dystrophy Patients 7/10/2014
Salix Pharmaceuticals, Ltd. (SLXP) Surges On Encouraging Phase 3 Results For Rifaximin; Stock Up +13.51% At Market Close (July 1, 2014) 7/2/2014
Biogen Idec, Inc. (Massachusetts) (BIIB), AbbVie (ABBV)'s Once-A-Month Drug Daclizumab Slows Multiple Sclerosis Episodes, Safety Issues Reoccur 6/17/2014
Cambridge-Based bluebird bio (BLUE)'s Gene Therapy Quickly Halts Blood Disease In Small Study; Stock Up 32.08% At Market Close (June 16, 2014) 6/17/2014
Achillion Pharmaceuticals, Inc. (ACHN) Surges As The FDA Lifts Hold On Hepatitis C Trial; Stock Up +83.29% At Market Close (June 10, 2014) 6/11/2014
GlaxoSmithKline (GSK) Launches Huge Phase 3 Study For Heart Drug Losmapimod 6/9/2014
Vertex Pharmaceuticals (MA) (VRTX) Reports Positive Ivacaftor Study Data, Plans To Initiate Larger Phase 3 Study 6/4/2014
Gilead Sciences, Inc. (GILD)'s Respiratory Syncytial Virus (RSV) Drug GS-5806 Wows In Phase 2 Trial 5/27/2014
Isis Pharmaceuticals, Inc. (ISIS) Surges As Blood Thinner Drug ISIS-FXI Succeeds In Phase 2 Trial; Stock Up 7.54% At Market Close (May 22, 2014) 5/23/2014
InterMune, Inc. (ITMN) Rises After Fatal Lung Disease Drug Slows Damage In Phase 3 Study 5/20/2014
Mylan Inc. (MYL)'s Necitumumab Improves Overall Survival In Largest Ever Phase 3 Study In First-Line Treatment Of Stage IV Squamous Non-Small Cell Lung Cancer 5/15/2014
Vertex Pharmaceuticals (MA) (VRTX) Release: Addition Of VX-661 To KALYDECO® (Ivacaftor) Improves Lung Function In People With CF Who Are Heterozygous For The F508del And G551D Mutations In 28-Day Phase 2 Proof-Of-Concept Study 5/2/2014
One Of A Kind Trial To Test 14 AstraZeneca PLC (AZN), Pfizer Inc. (PFE) Drugs At The Same Time 4/18/2014
Baxter International, Inc. (BAX) Drug BAX 111 Treats 100 Percent Of Bleeding Episodes In Small Phase 3 Trial 4/17/2014
Biogen Idec, Inc. (Massachusetts) (BIIB)'s Blood Disorder Drug Succeeds In Phase 3 Trial 4/10/2014
Alkermes plc (ALKS) Pulls Off Phase 3 Win for Long-Lasting Schizophrenia Drug 4/9/2014
Pfizer Inc. (PFE) Continues Its Streak, Phase 2 Breast Cancer Results Wows Investors And Researchers 4/8/2014
Endocyte, Inc. (ECYT) Doubles After Drug Shown To Slow Lung Cancer In Phase 2b Study 3/24/2014
Bay Area's InterMune, Inc. (ITMN) Gains As Boehringer Ingelheim Corporation's Rival Drug Shows Mixed Results 3/24/2014
Geron Corporation (GERN) Says FDA Halts Patient Enrollment In Another Cancer Trial 3/21/2014
Amgen (AMGN) Drug Meets Phase 3 Goals For Those With High Genetic Cholesterol 3/18/2014
Intercept Pharmaceuticals (ICPT) Drug Scores Pivotal Phase 3 Win Against Rare Liver Disease 3/18/2014
Raptor Pharmaceutical Inc. (RPTP) Surges As Huntington's Drug Meets Study Endpoints 2/21/2014
PRANA Biotechnology (PRAN) Soars As Brain Disorder Drug Succeeds In Phase 2 Trial; Stock Up +39.31% At Market Close (February 18, 2014) 2/19/2014
Shire plc Scraps Vyvanse® For Depression After Failed Phase 3 Trials 2/7/2014
Furiex Pharmaceuticals, Inc. (FURX) Shares Double As Irritable Bowel Drug Succeeds In Phase 3 Trials 2/5/2014
AbbVie (ABBV)'s Interferon-Free Hepatitis C Cocktail Excels In Ph3 Study 2/3/2014
ArQule, Inc. (ARQL) Soars As FDA Panel Favors Continuation Of Liver Cancer Drug Study, Stock Up +6.78% At Market Close (January 17, 2014) 1/17/2014
Sarepta Therapeutics (Formerly known as AVI BioPharma, Inc.) (SRPT) Surges Following Results Of Phase 2b Eteplirsen Therapy 1/17/2014
As Big Biotech Talks Cancer Vaccines, Bay Area's Aduro Biotech Nails Mid-Stage Pancreatic Cancer Study 1/16/2014
Intercept Pharmaceuticals (ICPT) Falls As CEO Says It May Need Help Big Pharma's Help 1/14/2014
Neurocrine Biosciences, Inc. (NBIX) Rockets On Positive Phase 2 Movement Disorder Drug Data; Stock Up +75.56% At Market Close (January 7, 2014) 1/8/2014
Cubist Pharmaceuticals, Inc. (CBST) Takes Off As Antibiotic Succeeds In Late-Stage Trial 12/18/2013
Novartis AG (NVS) Bone Marrow Cancer Drug Wows In Late-Stage Study 12/9/2013
Johnson & Johnson (JNJ), Pharmacyclics, Inc. (PCYC)'s Closely Watched Leukemia Drug Effective In Long Term Study 12/9/2013
Geron Corporation (GERN) Soars After Study Shows Bone Marrow Drug's Benefit 12/9/2013
Eli Lilly and Company (LLY)'s Depression Drug, Edivoxetine, Fails Late-Stage Trials 12/6/2013
Cubist Pharmaceuticals, Inc. (CBST)'s Urinary Tract Infection Drug Succeeds In Phase 3 Study 11/27/2013
Amgen (AMGN)'s Experimental Heart Drug Appears To Be Safe, Cuts LDL By Half At 1 Year Study 11/20/2013
AbbVie (ABBV), Enanta Pharmaceuticals, Inc.'s Hepatitis C Treatment Helps 96 Percent Of Patients In Phase 3 Studies 11/19/2013
GlaxoSmithKline (GSK) Heart Drug Misses Goal In Major Study 11/13/2013
Geron Corporation (GERN) Skyrockets as Cancer Drug is Highly Effective in Trial, Shares Up +44.72% @ Market Close (November 7, 2013) 11/8/2013
Astellas Pharma Inc. (ALPMY), Medivation, Inc. (MDVN) Prostate Cancer Drug Meets Phase 3 Trial Goals 10/22/2013
Ariad Pharmaceuticals, Inc. (ARIA) Discontinues Phase 3 Study of Cancer Drug Iclusig; Shares Decimated, Falls -40.67% at Market Close (October 18, 2013) 10/22/2013
Vertex Pharmaceuticals (MA) (VRTX)'s VX-509 Showed Positive Results for Rheumatoid Arthritis in Phase 2b Study 10/21/2013
Sanofi (France) (SAN.PA), Regeneron Pharmaceuticals, Inc. (REGN) Drug Slashes Cholesterol in Phase 3 Trial 10/21/2013
Gilead Sciences, Inc. (GILD)'s Idelalisib Works Against Leukemia, Phase 3 Trial Stopped Early; Stock Up +6.42% at Market Close (October 10, 2013) 10/14/2013
GlaxoSmithKline (GSK), ProSensa Holding N.V. (RNA)'s Muscular Dystrophy Drug Fails in Phase 3 Trial; ProSensa Stock Plunges -70.25% at Market Close on September 20, 2013 9/23/2013
Isis Pharmaceuticals, Inc. (ISIS) Rises on Positive Phase 1 Spinal Muscular Data 9/20/2013
Kythera Biopharmaceuticals (KYTH)' Drug Successfully Reduces Double Chin in Studies 9/19/2013
Bristol-Myers Squibb Company (BMY) Prostate Cancer Treatment Falls Short in Phase 3 Trial 9/13/2013
Celgene International Sárl (CELG) Reports POMALYST Met Prrimary Endpoint in Phase 3 Trial 9/5/2013
GlaxoSmithKline (GSK)'s Crohn's Disease Drug Fails Phase 3 Trial, ChemoCentryx, Inc. (CCXI) Stock Falls -32.12% on Friday at Market Close (August 23, 2013) 8/26/2013
Incyte Corporation (INCY) Surges on Positive Phase 2 Pancreatic Cancer Data; Stock Rockets +33.48% Wednesday, August 21, 2013 at Market Close 8/23/2013
Sarepta Therapeutics (Formerly known as AVI BioPharma, Inc.) (SRPT) Up, Then Down, on DMD Competitor's Trial Results 8/21/2013
MannKind Corporation (MNKD) Rockets on Positive Drug Data 8/16/2013
Vertex Pharmaceuticals (MA) (VRTX) Shares Rocket as CF Drug Impresses in Phase 3 Study 8/1/2013
Vertex Pharmaceuticals (MA) (VRTX) Tanks as FDA Puts Hold on Hep C Trial 7/30/2013
Isis Pharmaceuticals, Inc. (ISIS) Drug Reduces Blood Fat by 64 Pct in Phase 2 Study 7/24/2013
Array BioPharma, Inc. (ARRY)'s ARRY-502 Meets Goals in Asthma Study 7/23/2013
Celgene Corporation (CELG)'s Revlimid Improves Survival in Blood Cancer Patients 7/12/2013
Alnylam Pharmaceuticals (ALNY) Reports Positive Top-Line Results for ALN-TTRsc 7/11/2013
Janssen Research & Development's Ibrutinib Monotherapy Shows Efficacy in Patients With MCL or DLBCL 6/17/2013
Amgen (AMGN) Shows Off Phase 3 Ovarian Cancer Data 6/14/2013
Merck & Co., Inc. (MRK) Melanoma Drug Shrinks Tumors in 38 Percent of Patients: Study 6/4/2013
Clovis Oncology (CLVS) Shares Almost Double on Cancer Drug Trial 6/4/2013
Alkermes plc (ALKS) Unveils Full Mid-Stage Data on Depression Drug 5/31/2013
Pfizer Inc. (PFE) Halts Study of Non-Hodgkin's Lymphoma Drug 5/29/2013
Bristol-Myers Squibb Company (BMY) Drug Cocktail Stymies Melanoma Tumors 5/17/2013
Experimental Gilead Sciences, Inc. (GILD) Drug Effective in Early-Stage Leukemia Trial 5/16/2013
Infinity Pharmaceuticals Inc. (INFI) Announces Clinical Data to be Presented at American Society of Clinical Oncology and ICML 5/16/2013
Amgen (AMGN) Late-Stage Trial of Colon Cancer Drug Meets Goal 5/10/2013
Vertex Pharmaceuticals Incorporated (VRTX) Booms on Cystic Fibrosis Combo Drug Study 4/23/2013
Alkermes plc (ALKS) Has Jumped to a New High on Study Results 4/17/2013
FDA Asks ACADIA Pharmaceuticals, Inc. (ACAD) to Skip Late Stage Study and File NDA After Successful Results 4/11/2013
GlaxoSmithKline (GSK) Muscular Dystrophy Drug Reaches Primary Objective in Study 4/10/2013
Liver Toxicity Brings Melanoma Study on Bristol-Myers Squibb Company (BMY)/Roche (RHHBY) Drugs to a Halt 4/4/2013
Amgen (AMGN)'s Melanoma Drug Shows Promise in Key Trial 3/20/2013
Biogen Idec, Inc. (Massachusetts) (BIIB)'s Injectable MS Drug Cut Relapse Rate by 36 Pct 3/20/2013
Merck & Co., Inc. (MRK) Says a Crucial Vytorin Study Will Continue 3/13/2013
Celgene Corporation (CELG)'s Apremilast Succeeds in Phase 3 Psoriasis Trial 3/5/2013
FDA Halts Amgen (AMGN) Trial After Teen Death 3/4/2013
AbbVie (ABBV) Suspends Five Clinical Trials of Leukemia Therapy After Patient Deaths 2/27/2013
Genzyme Corporation (GENZ) Touts Positive Ph3 Drug Data 2/19/2013
Gilead Sciences, Inc. (GILD) Sees Positive Results From Late-Stage Hepatitis C Treatment Study 2/19/2013
Eli Lilly and Company (LLY) to Cease Tabalumab Phase 3 RA Program 2/8/2013
Celsion Corporation (CLN)'s Plummets on Phase 3 Liver Cancer Failure 2/1/2013
Pfizer Inc. (PFE) Reports Positive Results in Studies of Toviaz, Pristiq, Chantix 1/24/2013
Celgene (CELG)'s Abraxane Keeps Pancreatic Pts Alive an Extra Two Months in Trial 1/24/2013
Teva Pharmaceutical Industries Limited (TEVA)'s NUVIGIL® Fails Phase 3 Trial Again 1/23/2013
Genentech (RHHBY) Takes Exelixis, Inc. (EXEL) Drug Into Phase III Melanoma Trial 1/22/2013
The Medicines Company (MDCO) Jumps on Anti-Clotting Drug Study 1/9/2013
Genentech (RHHBY) Preps for $100 Million Alzheimer's Trial 12/19/2012
Oncolytics Biotech Inc. (ONC.TO) Soars on Positive Phase 3 Head and Neck Cancer Data 12/13/2012
Celgene (CELG)'s Pomalidomide Helps in Myeloma After Others Fail 12/12/2012
Stunning Data for Ambit Biosciences/Astellas Pharma Inc. (YPH.BE) AML Drug 12/11/2012
Pfizer Inc. (PFE) New Breast Cancer Drug Heralded as Breakthrough 12/10/2012
ViiV Healthcare Says Phase III Data From VIKING-3 Dolutegravir Study Encouraging 11/14/2012
Johnson & Johnson (JNJ) Isn't Giving Up on Alzheimer Drug 11/13/2012
Clavis Pharma ASA, Clovis Oncology (CLVS) Tank as Pancreatic Cancer Drug Fails Late-State Test 11/12/2012
Amgen (AMGN) Drug Cuts Bad Cholesterol Up to 66 Pct in Patients - Trial 11/7/2012
Biogen Idec, Inc. (Massachusetts) (BIIB) Hemophilia Drug Wows in Phase 3 Study 11/1/2012
Bayer HealthCare (BAY)'s Lung Drug Shows Promise in Phase 3 Study 10/23/2012
Pfizer Inc. (PFE) Kidney Cancer Drug Fails as Initial Treatment 10/18/2012
Genentech (RHHBY)'s T-DM1 Stuns as Approval Creeps Up 10/10/2012
Sanofi (France) (SAN.PA)'s Gaucher Pill Meets Goal in Phase 3 Trial 10/2/2012
Pfizer Inc. (PFE)'s RA Drug Tofacitinib Tops Methotrexate in Phase III 9/18/2012
Threshold Pharmaceuticals, Inc. (THLD) Plummets on Pancreatic Cancer Drug Study Survival Results 9/17/2012
Sanofi (France) (SAN.PA) Dengue Vaccine Less Effective Than Hoped 9/12/2012
Roche (RHHBY) Ramps Up Alzheimer's Drug Trial as Rivals Stumble 9/11/2012
Merck & Co., Inc. (MRK) Insomnia Drug Shows Positive Phase III Results 9/11/2012
Bristol-Myers Squibb Company (BMY) Ends Hepatitis C Development After Patient Death; Eats a $1.8 Billion Loss 8/27/2012
Idenix Pharmaceuticals, Inc. (IDIX) Hepatitis C Drug Put on Partial Hold 8/17/2012
Roche (RHHBY) Says Avastin Slows Brain Cancer Tumor Growth 8/10/2012
Amgen (AMGN) Halts Pancreatic Cancer Trial After Drug Failure 8/10/2012
Pfizer Inc. (PFE), Johnson & Johnson (JNJ) Scrap Alzheimer's Drug After Phase III Study Fails 8/8/2012
Roche (RHHBY) Moves Secret Heart Drug to Phase III Trial 7/25/2012
Biogen Idec, Inc. (Massachusetts) (BIIB), Bayer AG (BAY.F) Drugs Fail to Slow MS Progression 7/19/2012
Baxter International, Inc. (BAX) Alzheimer's Drug Keeps Four Patients Stable for 3 Years 7/19/2012
Alnylam Pharmaceuticals (ALNY) Gains on Treatment Data for Deadly Nerve Disease 7/18/2012
Merck & Co., Inc. (MRK) Bone Drug Shows Benefits So Trial is Stopped 7/16/2012
Pfizer Inc. (PFE): Xalkori Improves Lung Cancer Patients' Survival in Phase III Trial 6/19/2012
Johnson & Johnson (JNJ) Prostate Cancer Drug So Effective Trial Stopped 6/5/2012
Bristol-Myers Squibb Company (BMY) Immune Drug Shows Promise in Three Cancers, Success May Spur Industry Race 6/5/2012
ImmunoGen, Inc. (IMGN) Announces Development of Trastuzumab Emtansine for Early Stage HER2-Positive Breast Cancer 6/4/2012
GlaxoSmithKline (GSK) Melanoma Drugs Beat Chemo in Pivotal Trials 6/4/2012
Eli Lilly and Company (LLY)'s Diabetes Drug Meets Mid-stage Trial Goal 5/23/2012
GlaxoSmithKline (GSK)'s Melanoma Cocktail Slows Cancer in Study 5/21/2012
Boehringer Ingelheim Corporation Reports Convincing Data for Lung Cancer Therapy 5/17/2012
Pfizer Inc. (PFE)'s Torisel Fails Phase III Renal Cell Carcinoma Study in Showdown Against Bayer HealthCare (BAY)'s Nexavar 5/16/2012
Vertex Pharmaceuticals (MA) (VRTX) Soars as Cystic Fibrosis Drug Regimen Improves Patients’ Breathing 5/8/2012
Gilead Sciences, Inc. (GILD)-Bristol-Myers Squibb Company (BMY)'s Experimental Hepatitis C Drug Cured 88% Post-Therapy 4/20/2012
GlaxoSmithKline (GSK) to File GLP-1 Diabetes Drug Albiglutide as Data Impresses 4/4/2012
Keryx Biopharmaceuticals (KERX), AEterna Zentaris (AEZS) Colorectal Cancer Drug Fails Trial 4/3/2012
New Genentech (RHHBY) Breast Cancer Drug Shows Late Stage Trial Success 4/2/2012
AVI BioPharma, Inc. (AVII): Eteplirsen Study Shows No Significant Improvement in Walking 4/2/2012
AstraZeneca PLC (AZN), Targacept, Inc. (TRGT) Give Up on Antidepressant Drug After All Four Phase 3 Studies Fail 3/21/2012
Omeros Corporation (OMER)' Eye Drug OMS302 Meets Phase 3 Clinical Trial Goal 3/14/2012
Anthera Pharmaceuticals, Inc. (ANTH) Tanks as it Halts Phase III VISTA-16 Heart Drug Trial 3/13/2012
Johnson & Johnson (JNJ)'s Zytiga Scores Big Win, Hurts Dendreon Corporation (DNDN), Helps Medivation, Inc. (MDVN) 3/9/2012
Gilead Sciences, Inc. (GILD)’s Four-in-One AIDS Pill is Effective in Study 3/8/2012
Threshold Pharmaceuticals, Inc. (THLD) Soars on Positive Phase 2b Pancreatic Cancer Trial Results 2/22/2012
Actelion Ltd. (ALIOF.PK) CEO Says 120 Patients Died in Lung Drug Study 2/21/2012
Takeda Pharmaceutical Co. Ltd. (TKDG.DE)'s Inflammatory Bowel Disease Drug Meets Phase 3 Targets 2/21/2012
Gilead Sciences, Inc. (GILD) Drops as Patients Relapse on Hepatitis C Drug 2/21/2012
Medivation, Inc. (MDVN) Soars as Prostate Cancer Drug is Well-tolerated in Phase 3 Trial 2/3/2012
Bristol-Myers Squibb Company (BMY) Hepatitis C Pills Clear Virus Without Injections 1/20/2012
Pfizer Inc. (PFE) Ditches $725 Million Medivation, Inc. (MDVN) Pact as Phase 3 Alzheimer Trial Disappoints 1/20/2012
Bayer HealthCare (BAY)'s Colorectal Cancer Drug Regorafenib Shows Promise, Improves Overall Survival Rate by 29 Percent 1/18/2012
Roche (RHHBY)'s Avastin Disappoints Against Ovarian Cancer 1/3/2012
Study Challenges Bristol-Myers Squibb Company (BMY) on Bristol-Myers Squibb Company (BMY) and Sanofi (France) (SAN.PA)'s Plavix 12/29/2011
Genentech (RHHBY)'s Two-Drug Strategy Raises the Bar in Breast Cancer, Positive Phase III Results Reported 12/9/2011
Latest Data on Novartis AG (NVS) Afinitor Confirms Efficacy 12/9/2011
GlaxoSmithKline (GSK) Drug Fails to Hit Goal in Breast Cancer Trial 12/9/2011
Gilead Sciences, Inc. (GILD)'s Cobicistat Shows Efficacy in Phase 3 Study 12/7/2011
Regeneron Pharmaceuticals, Inc. (REGN)-Bayer HealthCare (BAY) Drug Matches Lucentis at 2 Years in Fewer Doses 12/6/2011
Bristol-Myers Squibb Company (BMY), Pfizer Inc. (PFE) Clot Drug Fails to Help Ill Patients 11/15/2011
Genzyme Corporation (GENZ) MS Drug Significantly Reduces Relapse, Disability in Phase III Trial 11/15/2011
Eli Lilly and Company (LLY) Experimental Drug Doubles Good Cholesterol in Race With Merck & Co., Inc. (MRK), Roche (RHHBY) 11/15/2011
Roche (RHHBY)'s New MS Drug "Cuts Relapses by 80 Percent" in Phase 2 Trial 11/4/2011
Shire plc Soars on Positive Phase 3 Prostate Cancer Data 11/4/2011
Biogen Idec, Inc. (Massachusetts) (BIIB)'s Oral MS Drug Shines in Phase 3 Study 10/24/2011
GlaxoSmithKline (GSK)'s Malaria Vaccine Works in Major Trial 10/21/2011
Teva Pharmaceutical Industries Limited (TEVA) and Active Biotech AB (BTPC) Laquinimod Trial for MS Treatment Yields Positive Results 10/20/2011
Halozyme Therapeutics, Inc. (HALO) Announces Positive Results from Roche (RHHBY)'s Subcutaneous Herceptin Phase 3 Trial 10/19/2011
Merck & Co., Inc. (MRK)'s ISENTRESS(R) (raltegravir) in Combination Therapy Shows Benefits Over Efavirenz 10/13/2011
VA Halts Roche (RHHBY)'s Avastin for Eye Disease; Rival Regeneron Pharmaceuticals, Inc. (REGN)'s Stock Surges 9/23/2011
Gilead Sciences, Inc. (GILD) Bumps Up Filing Timeline for Quad Pill, HIV Med Outperforms Rival in Study 9/21/2011
Nektar Therapeutics (CA) (NKTR) Release: Positive Results from Phase 2 Clinical Study of NKTR-102 in Metastatic Breast Cancer Presented in Oral Session at the American Society of Clinical Oncology 2011 Breast Cancer Symposium 9/12/2011
Pfizer Inc. (PFE)'s Arthritis Pill Tofacitinib Matches Abbott Laboratories (ABT)'s Humira in Final Studies 9/9/2011
AstraZeneca PLC (AZN)'s Crestor Fails to Beat Pfizer Inc. (PFE)'s Lipitor 9/6/2011
Amgen (AMGN), Cytokinetics, Inc. (CYTK) Heart Failure Class Shows Promise in Phase II 8/22/2011
Endo Pharmaceuticals (ENDP) Terminates Pain Program After Failed Trial; Ends Pact With Grunenthal GmbH 8/19/2011
Topline Results for GlaxoSmithKline (GSK)'s Second Phase III Parkinson's Drug Study 8/16/2011
Gilead Sciences, Inc. (GILD)'s Quad JOV Drug Shows Positive Results in Phase III Trial 8/15/2011
Biogen Idec, Inc. (Massachusetts) (BIIB) and Abbott Laboratories (ABT) Report Top-Line Positive Results for Daclizumab HYP Trial in RRMS 8/10/2011
GlaxoSmithKline (GSK)-Pfizer Inc. (PFE) AIDS Pill May Dislodge Bristol-Myers Squibb Company (BMY)'s, Study Suggests 7/28/2011
Genentech (RHHBY) Drug Impresses in Phase III Trial; to Seek Approval by Year End 7/27/2011
Amylin Pharmaceuticals, Inc. (AMLN), Alkermes (ALKS) Shares Jump on Success in Bydureon Study 7/27/2011
Sanofi (France) (SASY.PA)/Regeneron Pharmaceuticals, Inc. (REGN)'s Sarilumab Shines for Rheumatoid Arthritis, Fails in Ankylosing Spondylitis in Phase 2b Trial 7/27/2011
Nabi Biopharmaceuticals (NABI) Shares Plunge After Smoke-Cessation Drug Shown Ineffective in Study 7/19/2011
Vertex Pharmaceuticals (MA) (VRTX) Slides as Cystic Fibrosis Drug Shows Promise but Also Raises Questions in Phase II Trial 6/30/2011
Roche (RHHBY) Melanoma Drug Cuts Risk Of Death By 63 Percent; Bests Bristol-Myers Squibb Company (BMY) In Study 6/29/2011
Bristol-Myers Squibb Company (BMY), Pfizer Inc. (PFE) Blood Thinner Tops Warfarin in Stroke Study, Wows Investors 6/29/2011
Pfizer Inc. (PFE) Lung Cancer Pill May Double Survival 6/29/2011
Exelixis, Inc. (EXEL) Drug Slows Prostate Cancer Spread In Trial But Also Reports Deaths in Study 6/8/2011
Pfizer Inc. (PFE) Presents New Phase 3 Data Showing Axitinib Significantly Extended Progression-Free Survival Compared With Sorafenib In Patients With Previously-Treated Advanced Renal Cell Carcinoma 5/19/2011



//-->